Bristol-Myers Squibb has successfully completed its acquisition of MyoKardia in an all cash transaction for approximately $13.1 billion.
“We are excited to welcome MyoKardia colleagues to Bristol Myers Squibb. The MyoKardia team has revolutionized cardiovascular treatments to address significant unmet medical needs, and we look forward to helping more patients together,” said Giovanni Caforio, M.D., Board Chair and Chief Executive Officer of Bristol Myers Squibb.